• Autologous transplants have the advantage of lower risk of infection during the immune-compromised portion of the treatment, since the recovery of immune function is rapid. (wikipedia.org)
  • Donors for allogeneic transplants may be related or unrelated to the recipient. (medscape.com)
  • In syngeneic transplants, the donor is the identical twin of the recipient. (medscape.com)
  • Allogeneic transplants are further categorized by the degree of human leukocyte antigen (HLA) match between the donor and recipient. (medscape.com)
  • Although outcomes after HSCT have improved markedly since transplants were first utilized, infection remains an important source of morbidity. (medscape.com)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Haematopoietic stem cell transplants have been performed in more than 1 500 000 patients (both autologous and allogeneic) to date.1 Although haematological cancers remain the main indication, haematopoietic stem cell transplants are increasingly considered in the treatment of non-malignant disorders and genetic diseases such as haemoglobinopathies (sickle cell anaemia, thalassaemia) that can benefit greatly from this type of transplant. (who.int)
  • Infection and graft-versus-host disease are major complications of allogeneic HSCT. (wikipedia.org)
  • Cardiac complications have been described in HSCT with the majority of reported cardiac complications during HSCT attributed to the use of high-dose cyclophosphamide [30]. (slideshare.net)
  • HSCT make it an aggressive process, causing consists of painless intravenous infusion of healthy toxicity and can generate significant complications hematopoietic stem cells (HSC) extracted from bone and several side effects adding feelings of worry, marrow (BM), peripheral blood (PB) and placental anguish, anxiety, among others (KUBA et al. (bvsalud.org)
  • The study suggests that haploidentical HSCT shows comparable OS, LFS, and GRFS to HLA-matched HSCT in pediatric patients with acceptable complications, and can therefore be recommended as an effective alternative for this population. (blood-genomics.com)
  • Non-myeloablative, so-called mini transplant (microtransplantation) procedures, have been developed requiring smaller doses of preparative chemotherapy and radiation therapy, allowing HSCT to be conducted in the elderly and other patients who would otherwise be considered too weak to withstand a conventional treatment regimen. (wikipedia.org)
  • The mediannumber of chemotherapy regimens was 2 after tositumomab/iodine-131 tositumomaband prior to HSCT (range: 1-4). (cancernetwork.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • 2009 ). The underlying mechanism of HBV flare and reactivation following HSCT is likely to be related to impaired cellular immunity caused by prior chemotherapy and conditioning regimens. (springeropen.com)
  • Clinical Conditioning Not only chemotherapy and/or radiotherapy are required for the success of HSCT but also cellular immunotherapy. (mycareerpeer.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • Case presentation Here, we report a case of a refractory MCL in a patient who had relapsed after conventional chemotherapy and autologous CAR T cell therapy. (bmj.com)
  • In recent years, especially after the advent of reduced intensity conditioning in the late 1990s, allogeneic HSCT is increasingly used in older patients and as an effective salvage strategy for patients with lymphoma or myeloma not responding to chemotherapy or autologous HSCT. (longdom.org)
  • For the study, the investigators conducted a retrospective analysis of clinical data from patients who underwent a HSCT between January 2010 and December 2016 at the Salvador Zubirán National Institute of Health Sciences and Nutrition. (contagionlive.com)
  • Data were collected between March and September of 2016, through the evaluation of the medical records of 43 patients who underwent HSCT and developed some type of psychological distress. (bvsalud.org)
  • This study analyzed the clinical outcomes of 119 pediatric acute leukemia patients who underwent haploidentical HSCT ( n =68) or human leukocyte antigen (HLA)-matched HSCT ( n =51). (blood-genomics.com)
  • For other cancers such as acute myeloid leukemia, though, the reduced mortality of the autogenous relative to allogeneic HSCT may be outweighed by an increased likelihood of cancer relapse and related mortality, so the allogeneic treatment may be preferred for those conditions. (wikipedia.org)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Despite prophylactic treatment of the patients with immunosuppressive drugs after allo-HSCT, GvHD is still associated with non-relapse mortality (NRM) and contributes around 25% of NRM. (frontiersin.org)
  • Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. (uchicago.edu)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • The primary endpoint will assess the effect of EN on D100 mortality. (biomedcentral.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • The greater the mismatch between donor and recipient, the higher the risk of graft versus host disease (GVHD). (medscape.com)
  • In GVHD, the donated stem cells view the recipient cells as foreign and attack recipient cells. (medscape.com)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • Reduced GvHD was hypothesized to be attributed to the lysis of the recipients antigen showing cells (APCs) reducing the incidence of GvHD while keeping GvL effect. (mycareerpeer.com)
  • Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT protocols often lead to graft versus host disease (GvHD). (biomedcentral.com)
  • The 3-year probability of total chronic graft-versus-host disease (GVHD) was 21.4% and 34.1% in the haploidentical and HLA-matched HSCT groups, respectively ( P =0.526). (blood-genomics.com)
  • It may be autologous (the patient's own stem cells are used), allogeneic (the stem cells come from a donor) or syngeneic (from an identical twin). (wikipedia.org)
  • Also, the incidence of patients experiencing rejection is very rare (and graft-versus-host disease impossible) due to the donor and recipient being the same individual. (wikipedia.org)
  • First, the use of autologous hematopoietic stem cells for gene therapy obviates the need for a matched bone marrow donor since each individual would serve as his or her own bone marrow stem cell donor. (nih.gov)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Donor and recipient pairs should be of identical ABO blood group, and in addition should be matched as closely as possible for HISTOCOMPATIBILITY ANTIGENS in order to minimize the likelihood of allograft rejection. (lookformedical.com)
  • These advantages have established autologous HSCT as one of the standard second-line treatments for such diseases as lymphoma. (wikipedia.org)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • Conclusions This case suggests that haplo-CAR T cell therapy can be effective in controlling lymphoma that failed to respond to autologous CAR T cell therapy and overcome limitation of autologous CAR T cells, thus may be one possible regimen before the era of off-the-shelf "universal" CAR T cell therapy. (bmj.com)
  • Alternative to varicella-zoster immune globulin (VZIG) for postexposure prophylaxis of VZV infection † in HSCT recipients. (drugs.com)
  • Although long-term prophylaxis not routinely recommended for prevention of recurrent VZV infections in HSCT recipients, such prophylaxis may be considered in those with severe, long-term immunodeficiency. (drugs.com)
  • We retrospectively identified HBsAg carrier patients (serum HBsAg-positive and HBV-DNA positive) who received ETV for prophylaxis of HBV flare among patients undergoing HSCT between September 2006 and August 2011. (springeropen.com)
  • The purpose of this study is to evaluate the effectiveness of vedolizumab when added to background aGvHD prophylaxis regimen compared to placebo and background aGvHD prophylaxis regimen on intestinal aGvHD-free survival by Day +180 in participants who receive allo-HSCT as treatment for a hematologic malignancy or myeloproliferative disorder. (mayo.edu)
  • In a new study, a team of investigators from Mexico set out to determine the presence and incidence of both latent and active tuberculosis in recipients and donors living in Mexico, a nation where tuberculosis is endemic. (contagionlive.com)
  • In the analysis, the investigators included 200 patients made up of 63 allogeneic-HSCT recipients, 74 autologous-HSCT recipients, and 63 HSCT donors. (contagionlive.com)
  • The study found that rates of latent tuberculosis were 17% in all-HSCT recipients, 24% in auto-HSCT, and 39% in donors. (contagionlive.com)
  • Identification of the major histocompatibility antigens of transplant DONORS and potential recipients, usually by serological tests. (lookformedical.com)
  • Immunocompromised patients who have received a hematopoietic stem cell transplant (HSCT) have an incidence of active tuberculosis infection that is 10 to 40 times higher than the general population. (contagionlive.com)
  • Although Entecavir (ETV) is a standard antiviral drug for HBV infection, the efficacy and safety of ETV therapy in HSCT are still unclear. (springeropen.com)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • 2009 H1N1 influenza infection in cancer patients and hematopoietic stem cell transplant recipients. (uchicago.edu)
  • This is the first reported case of HHV-6 infection affecting the striatum and presenting with Parkinsonism post-HSCT. (hhv-6foundation.org)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • or actively by prior immunization of the recipient with graft antigens which evoke specific antibodies and form antigen-antibody complexes which bind to the antigen receptor sites of the T-cells and block their cytotoxic activity. (lookformedical.com)
  • Here we review the data for the use of QuantiFERON-TB Gold In-Tube and T-SPOT.TB, the two currently available IGRAs, in immunocompromised adults, including persons infected with HIV, patients with immune-mediated inflammatory disorders, candidates for treatment with tumor necrosis factor-α inhibitors, patients receiving hemodialysis, solid-organ transplant recipients, and patients with cancer. (atsjournals.org)
  • He has successfully taken research discoveries to the bedside and has been instrumental in establishing many of the clinicial HSCT procedures and current clinical trials including HSCT for severe autoimmune diseases and HIV. (edu.au)
  • The rehabilitation centres should be qualified and experienced because this patient group exhibits problems that differ from those of patients who have undergone oncological therapies or autologous HCT. (mdpi.com)
  • Analysis of the 3-year cumulative recurrence rate suggested no significant difference between the haploidentical HSCT group and HLA-matched HSCT group (cumulative incidence, 32.7% vs. 31.2%, P =0.801). (blood-genomics.com)
  • Several studies show that malnutrition is an independent negative prognostic factor for the survival of children and adults affected by malignant haematological disease and treated by allo-HSCT [ 5 - 8 ]. (biomedcentral.com)
  • The 5-year probability of overall survival (OS) after allogeneic HCT was estimated to be 56% (95% confidence interval[CI], 55%- 57%) for patients receiving a transplant while in CR, and 22% (95% CI, 21%-23%) for those who were experiencing active disease. (apbmt.org)
  • Reconstitution of the gut microbiota of antibiotic-treated patients by autologous fecal microbiota transplant. (uchicago.edu)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Although AML is the most common indication for allogeneic HCT, the relatively small number of patients and the highly complex nature of the procedure often render prospective studies on HCT unfeasible. (apbmt.org)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • HBV-infected patients at high risk of HBV flare and reactivation are recommended to receive preemptive antiviral therapy following HSCT. (springeropen.com)
  • Lamivudine (LAM), an analogue of cytidine, is available for antiviral therapy in HSCT, (Tomblyn et al. (springeropen.com)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • PHASES OF IMMUNE RECOVERY specialists, HSCT unit and clinic staff, and public health pro- fessionals. (cdc.gov)
  • An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. (lookformedical.com)
  • In preparation for receipt of the stem cells, recipients undergo myeloablation to eliminate their own myeloid cells. (medscape.com)
  • The harvested stem cells are processed before infusion into the recipient. (medscape.com)
  • This article focuses on the common infections in patients who have undergone HSCT, the risk factors for these infections, and the approaches to their prevention and treatment. (medscape.com)
  • Treatment of dermatomal herpes zoster in immunocompromised patients † including transplant recipients and HIV-infected patients. (drugs.com)
  • To examine the efficacy and tolerability of ETV treatment in HSCT, we retrospectively identified 5 patients who received ETV for treatment of HBsAg carrier among patients undergoing HSCT in our institute. (springeropen.com)
  • Here, we describe HBsAg carrier patients administered ETV for treatment following HSCT, and consider its efficacy and tolerability. (springeropen.com)
  • Medical tests using autologous NK cells have shown the therapy to be nontoxic, however, they fail to show efficacy (7), which could become the result of inhibition by self-MHC-I. Allogeneic treatment therefore offers potential to offer an alternative therapy with improved effect. (mycareerpeer.com)
  • COHORT II: Patients with high-risk disease receive initial treatment with IHC within 70 days after hematopoietic engraftment (both neutrophils and platelets) after allogeneic HSCT. (bioseek.eu)
  • The purpose of this study is to assess the effect your disease and the treatment of allogeneic stem cell transplant has upon you before and after your treatment process through questionnaires at certain time points. (mayo.edu)
  • EN and PN need to be prospectively compared in order to assess their impacts and to provide treatment guidelines. (biomedcentral.com)
  • In ASTIS during the first year, 13 events, including 8 treatment-related deaths, occurred in the HSCT group and 8 events with no treatment-related deaths occurred in the control group (16.5% vs. 10.4%, respectively). (medscape.com)
  • The biological questions with MonoMAC center around whether the individual leukocyte compartments that are lost in MonoMAC (B-lymphocytes, NK cells, and monocytes) will be constituted with HSCT, and whether the residual recipient T-lymphocytes will represent an impediment to engraftment. (nih.gov)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Secondary endpoints will compare EN and PN with regards to the main haematological, infectious and nutritional outcomes. (biomedcentral.com)
  • Allogeneic HCT has been widely used, while autologous HCT, which is still useful, is less prevalent because of concerns around post-transplant relapse, as well as the recently extended application of allogeneic HCT. (apbmt.org)
  • The median time from tositumomab/iodine-131tositumomab therapy to HSCT was 554 days (range: 77-2,893 days). (cancernetwork.com)
  • Ganciclovir is drug of choice for prevention of CMV following autologous or allogeneic HSCT in adults, adolescents, and children. (drugs.com)
  • 1,000 adults with AML currently undergoing allogeneic HCT per year. (apbmt.org)
  • Several studies have reported the efficacy of LAM treatments in HSCT patients (Hsiao et al. (springeropen.com)